Somewhat Positive Press Coverage Somewhat Unlikely to Impact Kura Oncology (KURA) Share Price
News coverage about Kura Oncology (NASDAQ:KURA) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kura Oncology earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.4573221284287 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media stories that may have effected Accern Sentiment’s rankings:
- Kura Oncology Added to Nasdaq Biotechnology Index (finance.yahoo.com)
- Head to Head Comparison: Kura Oncology (KURA) & Its Competitors (americanbankingnews.com)
- Kura Oncology (KURA) vs. Its Rivals Head to Head Survey (americanbankingnews.com)
- What Is The Future Prospect For Healthcare And Kura Oncology Inc (undefined:KURA)? (finance.yahoo.com)
- Oppenheimer Analysts Give Kura Oncology (KURA) a $18.00 Price Target (americanbankingnews.com)
Shares of Kura Oncology (KURA) opened at $14.25 on Tuesday. Kura Oncology has a 1 year low of $5.60 and a 1 year high of $17.50. The company has a quick ratio of 13.48, a current ratio of 13.48 and a debt-to-equity ratio of 0.07.
A number of brokerages have weighed in on KURA. Oppenheimer set a $18.00 price target on Kura Oncology and gave the company a “buy” rating in a research report on Monday, December 11th. Cann reiterated a “buy” rating and issued a $17.50 price target on shares of Kura Oncology in a research report on Monday, December 11th. BidaskClub cut Kura Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, December 7th. ValuEngine cut Kura Oncology from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Finally, Citigroup upped their price target on Kura Oncology from $15.00 to $19.00 and gave the company a “buy” rating in a research report on Thursday, November 9th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. Kura Oncology currently has an average rating of “Hold” and an average price target of $17.90.
ILLEGAL ACTIVITY NOTICE: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.watchlistnews.com/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-kura-oncology-kura-share-price/1772321.html.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.